Developer docs
API playgroundTry for free, no card

Search company profiles

AVS Bio

Full company profile

uuid0007uy3

Namestring
AVS Bio
Legal namestring
Avian Vaccine Services, LLC
Websiteurl
avsbio.com
Company typeenum
Private
Founded yearint
1960
Descriptiontext

AVS Bio (legal entity Avian Vaccine Services, LLC) produces Specific Pathogen Free (SPF) eggs and adjacent laboratory biological products, and provides antibody discovery, protein production, and preclinical testing services for the development of biologics. The company operates 20+ facilities across the United States (Connecticut, New York, Illinois, Missouri) and the Netherlands (Utrecht, Oss), serving global biopharma, pharmaceutical, animal health, and diagnostics customers developing vaccines, therapeutics, and assays. Its core technology stack centers on a proprietary rPEx® recombinant protein expression platform using HEK293 and CHO cell lines (10 µg to 150 L scale, 4-week typical turnaround, endotoxin <1 EU/mg), multiple antibody discovery platforms (single B cell, phage display, hybridoma, rare hit magnification), GlymaxX® ADCC-enhancement licensed from ProBioGen, and bi-/multi-specific and VHH antibody production capabilities. The company has supported 10 antibodies that entered clinical trials, produced 23,000+ proteins and 1 billion+ SPF eggs since inception, and holds a 24-year USDA license.

The business model combines catalog product sales (SPF eggs, avian antigens, antisera, recombinant proteins, catalog antibodies with published unit pricing) with quote-based custom services spanning antibody discovery, protein production, cell line development, and preclinical testing. Custom work — including IND-enabling studies now offered via the RoukenBio partnership — is delivered through enterprise B2B direct sales with multi-year contracts, while smaller research customers transact through an online catalog with add-to-cart and quote-request functionality. Revenue mechanics are split between product sales (one-time/recurring catalog purchases) and professional services (custom antibody programs, large-scale protein expression, preclinical studies). The company is a private, PE-backed entity owned by Arlington Capital Partners, having previously operated as a subsidiary of Charles River Laboratories. Approximately 300 employees support operations, with strategic leadership under CEO Jac Price (appointed July 2023) and a European hub led by CSO Ilse Roodink and General Manager Roland Romijn.

Short descriptiontext

AVS Bio produces Specific Pathogen Free (SPF) eggs and provides antibody discovery, recombinant protein production, and preclinical testing services to global biopharma, pharmaceutical, animal health, and diagnostics customers developing vaccines, therapeutics, and assays.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNorwich, United States
HQ citystring
Norwich
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
SPF egg production, avian biologicals supply, antibody discovery services, recombinant protein expression, preclinical antibody testing
Industry4 codes
PRIMARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAMABAC
Poultry & Avian Production Veterinary Services
Healthcare & Life Sciences/Veterinary & Animal Health/Large Animal & Equine Veterinary Services
SECONDARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs
SECONDARYAFAEADAD
Hatcheries & Chick Production (Day-Old Chicks, Pullets)
NAICS code2 codes
  • Poultry Hatcheries112340
  • Poultry and Egg Production1123
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Agricultural Prod-Livestock & Animal Specialties200
Product category
Biologics Services and Biological Materials
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model6 records
1SPF Eggs and Avian Biologicals
TypeOne Time License
Description

Sale of Specific Pathogen Free eggs, SPF chickens, chicken cell products, avian antigens, avian antisera, and related biological materials. Core historical business supporting vaccine and biologics manufacturing.

avsbio.com
2Antibodies and Proteins Products
TypeOne Time License
Description

Catalog and custom antibodies, recombinant proteins, and related products sold to research and biopharma customers. Includes products like WNT Surrogate-Fc Fusion Protein, vWF domains, and Alpha-1-antitrypsin.

avsbio.com
3Antibody Discovery and Development Services
TypeProfessional Services
Description

Full-service antibody discovery including tool generation, immunization, discovery, characterization, developability profiling, optimization and engineering, cell line development, protein production, and preclinical testing.

avsbio.com
4Protein Production Services
TypeProfessional Services
Description

Recombinant protein production using rPEx® platform from research scale to large-scale (up to 150L). Includes bi- and multi-specific antibodies, VHH production, and ADCC-enhanced antibodies.

avsbio.com
5Preclinical Testing Services
TypeProfessional Services
Description

IND-enabling preclinical antibody testing through partnership with RoukenBio. Immunology and oncology assays including ADCC, ADCP, CDC, T cell, NK cell, and other immune cell assays.

avsbio.com
6Avian Services
TypeProfessional Services
Description

Diagnostic and regulatory testing services, IgY antibodies, and custom biologics/vaccine manufacturing support.

avsbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details3 tiers
1WNT Surrogate-Fc Fusion Protein - $15.99 per unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Product listed at $15.99 with 60% discount for new users on 25µg trial size (€85 excluding tax and shipping)

avsbio.com
2Negative Serum (Liquid) - $10.75
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Individual unit pricing for catalog products

avsbio.com
3Custom antibody discovery and development services - Quote-based
ModelOtherBilling cadenceMulti-year contract
Notes

Services are quote-based, not publicly disclosed. Customers contact sales team via form or phone for custom project pricing.

avsbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1rPEx®
Description

Proprietary recombinant protein expression platform using HEK293 and CHO cell lines for high-quality protein production from research to large-scale.

avsbio.com
+1 more record
Core offering1 text field

AVS Bio produces and supplies Specific Pathogen Free (SPF) eggs, avian biologicals (chicken cell products, avian antigens, antisera, IgY antibodies), catalog and custom antibodies, and recombinant proteins to research and biopharma customers. In parallel, the company delivers full-service antibody discovery and development — including tool generation, immunization, discovery, characterization, developability profiling, optimization and engineering, cell line development, protein production, and preclinical testing — to global pharmaceutical, biotechnology, and animal health customers developing vaccines, therapeutics, and diagnostics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 10 antibodies with supported development entered clinical trials
+5 more records
Product and service7 records
1SPF Eggs and Avian Biologicals
CategoryAvian Biologicals and SPF Eggs
Description

Specific Pathogen Free eggs and related avian biological materials (including SPF chickens, chicken cell products, avian antigens, avian antisera, mycoplasma/pullorum plate antigens, human influenza virus, Sendai virus, and other avian reagents) supplied to vaccine manufacturers, diagnostics developers, and biopharma companies for biologics production and testing.

2USDA-licensed FFM Products (IgY Antibodies)
CategoryUSDA-licensed Antibody Products
Description

USDA-licensed IgY antibodies and related avian antibody products supplied for veterinary and human health applications, leveraging AVS Bio's long-standing USDA license and IgY clinical experience (including the company's first IgY clinical study supported in 2020).

3Catalog and Custom Antibodies and Recombinant Proteins
CategoryAntibodies and Recombinant Proteins
Description

Catalog and custom antibodies and recombinant proteins across research areas including organoid research, inflammatory diseases, cell biology, complement/innate immunity, hematology, infectious diseases, molecular cell biology, oncology, and general research tools; produced via the proprietary rPEx® platform and sold to research and biopharma customers (including products like WNT Surrogate-Fc Fusion Protein, vWF domains, and Alpha-1-antitrypsin).

4Antibody Discovery and Development Services
CategoryAntibody Discovery and Development Services
Description

Full-service antibody discovery and development program for biopharma and biotechnology customers, covering tool generation, immunization, antibody discovery (single B cell, phage display, hybridoma, rare hit magnification), characterization, developability profiling, optimization and engineering, cell line development, protein production and purification, and preclinical testing.

5Recombinant Protein Production Services (rPEx® Platform)
CategoryProtein Production Services
Description

Recombinant protein production service using the proprietary rPEx® platform with HEK293 and CHO cell lines, supporting discovery through large-scale production up to 150 liters with endotoxin levels below 1 EU/mg and a typical 4-week turnaround; includes bi- and multi-specific antibodies (Fc-free formats), VHH antibody production (tag-free), and ADCC-enhanced antibodies via GlymaxX®.

6Preclinical Antibody Testing Services
CategoryPreclinical Testing Services
Description

IND-enabling preclinical antibody testing service delivered in partnership with RoukenBio, providing immunology and oncology assays such as ADCC, ADCP, CDC, T cell, NK cell, and other immune cell assays to support lead candidate prioritization and reduce translational risk before IND-enabling studies.

7Avian Services (Diagnostic, Regulatory Testing, Custom Biologics)
CategoryAvian Services
Description

Service portfolio covering avian diagnostic and regulatory testing, IgY antibody services, and custom biologics and vaccine manufacturing support for veterinary and human health customers.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Strategic partnership announced February 17, 2026, integrating AVS Bio's antibody discovery and development services with RoukenBio's mechanism-driven functional characterization using cell-based and primary immune cell assay systems. Creates an end-to-end antibody engine combining AVS Bio's design-focused discovery platforms with RoukenBio's immunology expertise. Aims to improve lead candidate prioritisation and reduce translational uncertainty before IND-enabling studies.

Strategic tierMinorTypeOthers
Description

Website development and marketing services partner credited in website footer.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Charles River Laboratories was AVS Bio's former parent company and remains a direct competitor in SPF egg production, animal health biological materials, and biologics services. Charles River's broader portfolio and global scale make it the most direct large-scale competitor in AVS Bio's core markets.

TypeDirect peer
Description

GenScript is a major contract service provider offering gene synthesis, protein expression, and antibody discovery services that directly compete with AVS Bio's rPEx® platform and multi-platform antibody discovery offering. Both serve biopharma and biotech customers with similar end-to-end workflows.

TypeDirect peer
Description

Bio-Techne is a major supplier of research antibodies, recombinant proteins, and related reagents that directly competes with AVS Bio's catalog antibodies and proteins business. Both serve global biopharma research customers with similar protein and antibody product portfolios.

TypeDirect peer
Description

Abcam is a leading supplier of research antibodies and related reagents that directly competes with AVS Bio's catalog antibody offerings. The connection is reinforced by AVS Bio CEO Jac Price's prior SVP role at Abcam.

TypeBroad incumbent
Description

Lonza is a large CDMO offering comprehensive biologics manufacturing, antibody production, and cell line development services that overlap with AVS Bio's protein production and antibody discovery offerings. As a global incumbent, Lonza competes for large biopharma accounts that AVS Bio also targets.

TypeDirect peer
Description

Cell Signaling Technology is a leading provider of highly validated research antibodies that directly competes with AVS Bio's catalog antibody business. Both serve the same life sciences research and biopharma development customer base.

TypeDirect peer
Description

Bio-Rad's Life Science segment offers antibodies, proteins, and bioprocessing products that compete directly with AVS Bio's catalog products. Both companies serve global biopharma and academic research customers with similar reagent and instrument offerings.

TypeBroad incumbent
Description

Sartorius is a leading bioprocessing equipment and consumables supplier that competes with AVS Bio in the broader biologics production value chain. Sartorius serves many of the same biopharma customers and is expanding into adjacent services that overlap with AVS Bio's offerings.

TypeBroad incumbent
Description

Eurofins provides bioanalytical testing, diagnostics, and biologics services that overlap with AVS Bio's avian testing services and antibody characterization offerings. Eurofins' global laboratory network competes for testing and characterization work from large biopharma customers.

TypeEmerging player
Description

Creative Biolabs is a CRO offering custom antibody discovery, engineering, and production services that directly compete with AVS Bio's antibody discovery and protein production business. Creative Biolabs focuses on niche biopharma customers with custom antibody engineering needs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AVS Bio

Biologics Services and Biological Materialsavsbio.com

AVS Bio produces Specific Pathogen Free (SPF) eggs and provides antibody discovery, recombinant protein production, and preclinical testing services to global biopharma, pharmaceutical, animal health, and diagnostics customers developing vaccines, therapeutics, and assays.

What AVS Bio does

AVS Bio (legal entity Avian Vaccine Services, LLC) produces Specific Pathogen Free (SPF) eggs and adjacent laboratory biological products, and provides antibody discovery, protein production, and preclinical testing services for the development of biologics. The company operates 20+ facilities across the United States (Connecticut, New York, Illinois, Missouri) and the Netherlands (Utrecht, Oss), serving global biopharma, pharmaceutical, animal health, and diagnostics customers developing vaccines, therapeutics, and assays. Its core technology stack centers on a proprietary rPEx® recombinant protein expression platform using HEK293 and CHO cell lines (10 µg to 150 L scale, 4-week typical turnaround, endotoxin <1 EU/mg), multiple antibody discovery platforms (single B cell, phage display, hybridoma, rare hit magnification), GlymaxX® ADCC-enhancement licensed from ProBioGen, and bi-/multi-specific and VHH antibody production capabilities. The company has supported 10 antibodies that entered clinical trials, produced 23,000+ proteins and 1 billion+ SPF eggs since inception, and holds a 24-year USDA license.

The business model combines catalog product sales (SPF eggs, avian antigens, antisera, recombinant proteins, catalog antibodies with published unit pricing) with quote-based custom services spanning antibody discovery, protein production, cell line development, and preclinical testing. Custom work — including IND-enabling studies now offered via the RoukenBio partnership — is delivered through enterprise B2B direct sales with multi-year contracts, while smaller research customers transact through an online catalog with add-to-cart and quote-request functionality. Revenue mechanics are split between product sales (one-time/recurring catalog purchases) and professional services (custom antibody programs, large-scale protein expression, preclinical studies). The company is a private, PE-backed entity owned by Arlington Capital Partners, having previously operated as a subsidiary of Charles River Laboratories. Approximately 300 employees support operations, with strategic leadership under CEO Jac Price (appointed July 2023) and a European hub led by CSO Ilse Roodink and General Manager Roland Romijn.

AVS Bio firmographics

Firmographics
Name
AVS Bio
Legal name
Avian Vaccine Services, LLC
Website
https://avsbio.com
Company type
Private
Founded year
1960
Operating status
Operating
Headcount range
101–250 employees
Short description
AVS Bio produces Specific Pathogen Free (SPF) eggs and provides antibody discovery, recombinant protein production, and preclinical testing services to global biopharma, pharmaceutical, animal health, and diagnostics customers developing vaccines, therapeutics, and assays.
Ownership category
akta.pro rank

AVS Bio industry classification

Industry
Product category
Biologics Services and Biological Materials
NAICS
Poultry Hatcheries (112340), Poultry and Egg Production (1123)
SIC
Biological Products, (No Disgnostic Substances) (2836), Agricultural Prod-Livestock & Animal Specialties (200)
akta.pro industry
PRIMARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAMABAC
Poultry & Avian Production Veterinary Services
Healthcare & Life Sciences/Veterinary & Animal Health/Large Animal & Equine Veterinary Services
SECONDARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs
SECONDARYAFAEADAD
Hatcheries & Chick Production (Day-Old Chicks, Pullets)

Keywords

  • SPF egg production
  • Avian biologicals supply
  • Antibody discovery services
  • Recombinant protein expression
  • Preclinical antibody testing

Where AVS Bio is headquartered

Location

Headquarters

HQ city
Norwich
HQ country
United States
HQ region
North America

Offices7 records

Markets served

AVS Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. SPF Eggs and Avian Biologicals: Sale of Specific Pathogen Free eggs, SPF chickens, chicken cell products, avian antigens, avian antisera, and related biological materials. Core historical business supporting vaccine and biologics manufacturing.
  2. Antibodies and Proteins Products: Catalog and custom antibodies, recombinant proteins, and related products sold to research and biopharma customers. Includes products like WNT Surrogate-Fc Fusion Protein, vWF domains, and Alpha-1-antitrypsin.
  3. Antibody Discovery and Development Services: Full-service antibody discovery including tool generation, immunization, discovery, characterization, developability profiling, optimization and engineering, cell line development, protein production, and preclinical testing.
  4. Protein Production Services: Recombinant protein production using rPEx® platform from research scale to large-scale (up to 150L). Includes bi- and multi-specific antibodies, VHH production, and ADCC-enhanced antibodies.
  5. Preclinical Testing Services: IND-enabling preclinical antibody testing through partnership with RoukenBio. Immunology and oncology assays including ADCC, ADCP, CDC, T cell, NK cell, and other immune cell assays.
  6. Avian Services: Diagnostic and regulatory testing services, IgY antibodies, and custom biologics/vaccine manufacturing support.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goWNT Surrogate-Fc Fusion Protein - $15.99 per unit
Unit PricingPay-as-you-goNegative Serum (Liquid) - $10.75
OtherMulti-year contractCustom antibody discovery and development services - Quote-based

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

AVS Bio product offering

Product offering

Core offering

AVS Bio produces and supplies Specific Pathogen Free (SPF) eggs, avian biologicals (chicken cell products, avian antigens, antisera, IgY antibodies), catalog and custom antibodies, and recombinant proteins to research and biopharma customers. In parallel, the company delivers full-service antibody discovery and development — including tool generation, immunization, discovery, characterization, developability profiling, optimization and engineering, cell line development, protein production, and preclinical testing — to global pharmaceutical, biotechnology, and animal health customers developing vaccines, therapeutics, and diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

  • rPEx®: Proprietary recombinant protein expression platform using HEK293 and CHO cell lines for high-quality protein production from research to large-scale.
  • GlymaxX®

Products and services

  • SPF Eggs and Avian Biologicals Specific Pathogen Free eggs and related avian biological materials (including SPF chickens, chicken cell products, avian antigens, avian antisera, mycoplasma/pullorum plate antigens, human influenza virus, Sendai virus, and other avian reagents) supplied to vaccine manufacturers, diagnostics developers, and biopharma companies for biologics production and testing.
  • USDA-licensed FFM Products (IgY Antibodies) USDA-licensed IgY antibodies and related avian antibody products supplied for veterinary and human health applications, leveraging AVS Bio's long-standing USDA license and IgY clinical experience (including the company's first IgY clinical study supported in 2020).
  • Catalog and Custom Antibodies and Recombinant Proteins Catalog and custom antibodies and recombinant proteins across research areas including organoid research, inflammatory diseases, cell biology, complement/innate immunity, hematology, infectious diseases, molecular cell biology, oncology, and general research tools; produced via the proprietary rPEx® platform and sold to research and biopharma customers (including products like WNT Surrogate-Fc Fusion Protein, vWF domains, and Alpha-1-antitrypsin).
  • Antibody Discovery and Development Services Full-service antibody discovery and development program for biopharma and biotechnology customers, covering tool generation, immunization, antibody discovery (single B cell, phage display, hybridoma, rare hit magnification), characterization, developability profiling, optimization and engineering, cell line development, protein production and purification, and preclinical testing.
  • Recombinant Protein Production Services (rPEx® Platform) Recombinant protein production service using the proprietary rPEx® platform with HEK293 and CHO cell lines, supporting discovery through large-scale production up to 150 liters with endotoxin levels below 1 EU/mg and a typical 4-week turnaround; includes bi- and multi-specific antibodies (Fc-free formats), VHH antibody production (tag-free), and ADCC-enhanced antibodies via GlymaxX®.
  • Preclinical Antibody Testing Services IND-enabling preclinical antibody testing service delivered in partnership with RoukenBio, providing immunology and oncology assays such as ADCC, ADCP, CDC, T cell, NK cell, and other immune cell assays to support lead candidate prioritization and reduce translational risk before IND-enabling studies.
  • Avian Services (Diagnostic, Regulatory Testing, Custom Biologics) Service portfolio covering avian diagnostic and regulatory testing, IgY antibody services, and custom biologics and vaccine manufacturing support for veterinary and human health customers.

Quantifiable outcome

  • 10 antibodies with supported development entered clinical trials
  • +5 more outcomes

Companies that use AVS Bio

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

AVS Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

AVS Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • RoukenBiocoreStrategic or Co-development Partner · 17 February 2026Strategic partnership announced February 17, 2026, integrating AVS Bio's antibody discovery and development services with RoukenBio's mechanism-driven functional characterization using cell-based and primary immune cell assay systems. Creates an end-to-end antibody engine combining AVS Bio's design-focused discovery platforms with RoukenBio's immunology expertise. Aims to improve lead candidate prioritisation and reduce translational uncertainty before IND-enabling studies.
  • Scaler MarketingminorOthersWebsite development and marketing services partner credited in website footer.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

AVS Bio competitors and assessment

Company assessment

Direct peers

  • Charles River Laboratories: Charles River Laboratories was AVS Bio's former parent company and remains a direct competitor in SPF egg production, animal health biological materials, and biologics services. Charles River's broader portfolio and global scale make it the most direct large-scale competitor in AVS Bio's core markets.
  • GenScript: GenScript is a major contract service provider offering gene synthesis, protein expression, and antibody discovery services that directly compete with AVS Bio's rPEx® platform and multi-platform antibody discovery offering. Both serve biopharma and biotech customers with similar end-to-end workflows.
  • Bio-Techne: Bio-Techne is a major supplier of research antibodies, recombinant proteins, and related reagents that directly competes with AVS Bio's catalog antibodies and proteins business. Both serve global biopharma research customers with similar protein and antibody product portfolios.
  • Abcam: Abcam is a leading supplier of research antibodies and related reagents that directly competes with AVS Bio's catalog antibody offerings. The connection is reinforced by AVS Bio CEO Jac Price's prior SVP role at Abcam.
  • Cell Signaling Technology: Cell Signaling Technology is a leading provider of highly validated research antibodies that directly competes with AVS Bio's catalog antibody business. Both serve the same life sciences research and biopharma development customer base.
  • Bio-Rad Laboratories: Bio-Rad's Life Science segment offers antibodies, proteins, and bioprocessing products that compete directly with AVS Bio's catalog products. Both companies serve global biopharma and academic research customers with similar reagent and instrument offerings.

Broad incumbents

  • Lonza: Lonza is a large CDMO offering comprehensive biologics manufacturing, antibody production, and cell line development services that overlap with AVS Bio's protein production and antibody discovery offerings. As a global incumbent, Lonza competes for large biopharma accounts that AVS Bio also targets.
  • Sartorius: Sartorius is a leading bioprocessing equipment and consumables supplier that competes with AVS Bio in the broader biologics production value chain. Sartorius serves many of the same biopharma customers and is expanding into adjacent services that overlap with AVS Bio's offerings.
  • Eurofins Scientific: Eurofins provides bioanalytical testing, diagnostics, and biologics services that overlap with AVS Bio's avian testing services and antibody characterization offerings. Eurofins' global laboratory network competes for testing and characterization work from large biopharma customers.

Emerging players

  • Creative Biolabs: Creative Biolabs is a CRO offering custom antibody discovery, engineering, and production services that directly compete with AVS Bio's antibody discovery and protein production business. Creative Biolabs focuses on niche biopharma customers with custom antibody engineering needs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AVS Bio social profiles

Digital presence

AVS Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AVS Bio leadership team

Management profile

Number of profiles

Profiles5 records

AVS Bio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

AVS Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AVS Bio M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AVS Bio

What does AVS Bio do?

AVS Bio produces and supplies Specific Pathogen Free (SPF) eggs, avian biologicals (chicken cell products, avian antigens, antisera, IgY antibodies), catalog and custom antibodies, and recombinant proteins to research and biopharma customers. In parallel, the company delivers full-service antibody discovery and development — including tool generation, immunization, discovery, characterization, developability profiling, optimization and engineering, cell line development, protein production, and preclinical testing — to global pharmaceutical, biotechnology, and animal health customers developing vaccines, therapeutics, and diagnostics.

Is AVS Bio a public or private company?

AVS Bio is a private company. It is classified as private equity controlled and is currently operating.

When was AVS Bio founded?

AVS Bio was founded in 1960. It employs 101 to 250 people.

Where is AVS Bio based?

AVS Bio is headquartered in Norwich, United States, in the North America region.

How does AVS Bio make money?

Six revenue lines are on record. SPF Eggs and Avian Biologicals are the primary driver. The others are antibodies and Proteins Products, antibody Discovery and Development Services, protein Production Services, preclinical Testing Services and avian Services.

Who are AVS Bio's main competitors?

Direct peers on record are Charles River Laboratories, GenScript, Bio-Techne, Abcam, Cell Signaling Technology and Bio-Rad Laboratories. Broad incumbents are Lonza, Sartorius and Eurofins Scientific. Creative Biolabs is listed as an emerging player.

Does AVS Bio have an API?

No public API is recorded for AVS Bio.

What industry is AVS Bio in?

AVS Bio's product category is Biologics Services and Biological Materials. Its primary akta.pro industry code is HLAMAKAH, Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA), with a secondary code of HLAMABAC, Poultry & Avian Production Veterinary Services. Its NAICS code is 112340 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0AVS Bio Acquires Biorbyt To Expand Global Biomaterials And Life Sciences Research PlatformAVS Bio acquired Biorbyt, a UK-based supplier of research antibodies, proteins, and biomaterials, to expand its product catalog and international distribution. Biorbyt's portfolio includes over one million stock-keeping units, and the deal strengthens AVS Bio's digital commerce capabilities. The combined business aims to serve researchers across pharmaceutical, biotechnology, and academic markets.citybizArlington Capital Partners-Backed AVS Bio Acquires BiorbytAVS Bio acquired Cambridge, UK-based Biorbyt, adding over 1 million life science research products and an ecommerce platform. Financial terms were not disclosed. The deal expands AVS Bio's biomaterials portfolio and digital distribution capabilities.Business Wire BlogAVS Bio, an Arlington Capital Partners Portfolio Company, Acquires Biorbyt Ltd.AVS Bio acquired Biorbyt Ltd., a global supplier of bio-reagents and antibodies, to expand its biomaterials offering and ecommerce capabilities. Biorbyt's catalog of over 1 million SKUs will be integrated into AVS Bio's platform, serving pharma, biotech, and academia. The acquisition aims to broaden AVS Bio's reach across geographies and customer segments.AijournAn AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the NumbersMindWalk Holdings Corp. (NASDAQ: HYFT) reported fiscal 2026 revenue up 46% year over year to C$15.6 million, with gross margin expanding to 58.8% and net loss narrowing by more than half to C$13.9 million, as the company signed its first two contracted recurring enterprise LensAI agreements, marking the first recurring platform revenue in its history. The company also completed its transformation into MindWalk Holdings Corp. from ImmunoPrecise Antibodies Ltd. and divested its Netherlands subsidiary to AVS Bio for approximately C$14.3 million. The results are preliminary pending the filing of the company's Annual Report on Form 20-F.AdvfnAn AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the NumbersMindWalk Holdings Corp. (NASDAQ: HYFT) reported fiscal 2026 results showing revenue up 46% year over year to C$15.6 million, with gross margin expanding to 58.8% and net loss narrowing by more than half to C$13.9 million. The company signed its first two contracted recurring enterprise LensAI agreements during the year, marking the first recurring platform revenue in its history. MindWalk also completed its transformation from ImmunoPrecise Antibodies Ltd., divested its Netherlands subsidiary to AVS Bio for approximately C$14.3 million, and regained Nasdaq listing compliance without reverse split or dilutive financing.Stock TitanMindWalk FY2026 Earnings: Revenue Up 46% to C$15.6MMindWalk Holdings Corp. reported fiscal 2026 results for the year ended April 30, 2026, with revenue up 46% year-over-year to $15.6 million and gross margin expanding to 59% as the company completed its strategic pivot to Bio-Native AI infrastructure. The company narrowed its net loss by more than half to $13.9 million and divested its Netherlands subsidiary ImmunoPrecise Antibodies (Europe) B.V. to AVS Bio for approximately $14.3 million, sharpening focus on its core BioIntelligence platform. Subsequent to year-end, MindWalk launched its ReefIQ platform in June 2026 and was added to the Russell 3000E and Russell Microcap Indexes, while regaining Nasdaq listing compliance without requiring a reverse split or dilutive financing.FierceBiotechImmunology CRO RoukenBio pens pact with AVS Bio for more predictable antibody developmentPreclinical CRO RoukenBio has entered into a partnership with Connecticut-based biologics discovery specialist AVS Bio to improve the predictability of therapeutic antibody development. The collaboration will combine AVS Bio's antibody discovery and computational expertise with RoukenBio's immunology assay platforms, integrating high-quality antibody discovery with early mechanism-driven functional characterization to help avoid late-stage trial failures. The partnership incorporates a data-driven approach intended to improve R&D decision-making across the drug development process.PharmiWeb.comRoukenBio and AVS Bio Announce Strategic Partnership to Integrate Design-Focused Antibody Discovery and Optimisation with Mechanism-Driven Functional CharacterisationRoukenBio and AVS Bio announced a strategic partnership on February 17, 2026, in Motherwell, Scotland, to integrate antibody discovery and development services with mechanism-driven functional characterisation for biotherapeutic developers. The collaboration creates an end-to-end antibody engine combining AVS Bio's design-focused discovery platforms with RoukenBio's cell-based and primary immune cell assay systems, aiming to improve lead candidate prioritisation and reduce translational uncertainty before IND-enabling studies. The companies stated the partnership reflects a shared philosophy that successful antibody therapeutics require both high-quality discovery and early, mechanism-driven validation in physiologically relevant biological systems.ArlingtoncapAVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities with Acquisition of ImmunoPrecise Antibodies Europe from ImmunoPrecise AntibodiAVS Bio, a portfolio company of Arlington Capital Partners, has acquired ImmunoPrecise Antibodies (Europe) B.V. from ImmunoPrecise Antibodies Ltd., expanding its European footprint and adding advanced antibody discovery and protein production capabilities. The acquisition integrates IPA Europe's facilities in the Netherlands into AVS Bio’s global network to serve pharmaceutical customers more effectively.AInvestAVS Bio Expands Capabilities in Antibody Discovery and Protein Production with Acquisition of ImmunoPrecise Antibodies EuropeAVS Bio acquired ImmunoPrecise Antibodies Europe B.V. on August 6, 2025, to expand its antibody discovery and protein production services in Europe. IPA Europe, based in the Netherlands, offers recombinant protein expression and scalable production for research and pre-clinical applications. The deal strengthens AVS Bio's biologics services portfolio and geographic reach.